TauRx to present update on pivotal Phase 3 study for the first tau-based disease modifying treatment for Alzheimer’s disease at J.P. Morgan Annual Healthcare Conference
Aberdeen, Scotland and Singapore, 12th January 2021 – TauRx Pharmaceuticals Ltd today announced it will be presenting its latest trial results at the invitation only J.P. Morgan 39th Annual Healthcare Conference 2021. Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx will present to delegates on 13th January 2021, 17:10 GMT, in the emerging markets section of the event. TauRx has recently completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer’s disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.
Professor Wischik commented “It is an honour to be invited to present at the J.P. Morgan Healthcare Conference and share our latest analysis of data from previous studies with the select audience. There remains an urgent need for a disease modifying treatment for dementia."
You can view the presentation here: TauRx Pharmaceuticals - Presentation of Latest Trial Data and Lucidity Progress.
Attedance at the J.P. Morgan Healthcare conference is by invitation only. The conference focuses on health leaders and transformers, who are working to change the current paradigms of health and wellness. It features guests who are advancing, developing, designing, applying and funding real solutions to improve personal and population health.